Tag Archives: Epic Sciences

September 2016—Genomic Health and Epic Sciences announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the U.S. through Genomic Health’s commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein in the nucleus of circulating tumor cells—information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer.

March 2016—Digital consults: options for getting from here to there: The U.S. digital pathology consultation marketplace is steadily gaining ground, largely owing to increased demand for international consultations. And those delving into digital consults are making a three-pronged decision: build your own system, install an off-the-shelf software solution, or sign up with a Web-based digital consultation network.

February 2016—Epic Sciences announced a collaboration with University of Pennsylvania’s Abramson Cancer Center on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells at a single cell resolution, that are predictive of response to personalized cancer therapeutics.